CNBC Mike Huckman interviewed with CEO of DNDN at the big biotech conferencewas just completed-study progresses.  The last 2% survival is within reach for later in the year. 

 

Says he is on the 10 yard line and needs to punch it in-I hate those sport analogies for bio drug development.  The last dude to use those analogies was the CEO of ENCY.  The company doesn't exist anymore.  I believe DNDN will dance with the FDA later this year once again.  One can hope it will be as crazy?

 

The time will come to jump this again-not yet!  This board will be gone.

 

Kutz